Professor Dr Christoph Wanner is a professor of medicine in the Division of Nephrology and Head of the Division of Nephrology in the Department of Medicine at the University Hospital of Würzburg, Germany. He is a visiting professor at Charles University, Prague, Czech Republic.
He is an executive committee member of Kidney Disease: Improving Global Outcomes; past chairman of the European Renal Association – European Dialysis and Transplant Association (ERO-EDTA) Registry; an international steering committee member of the Residual Risk Reduction Initiative; and an advisory board member of European Renal Best Practice.
Professor Wanner has published a significant number of scientific papers and articles on renal dialysis, Fabry disease, chronic kidney failure, LDLs, lipoprotein(a), type 2 diabetes, alpha-galactosidases, cardiovascular diseases and hydroxymethylglutaryl-CoA reductase inhibitors. He is editor-in-chief of the Journal of Renal Nutrition, an associate editor of the Nephrology Dialysis Transplantation Journal, and an editorial board member of Kidney International Supplements, Folia Biologica, Journal of the American Society of Nephrology, and Current Opinion in Nephrology and Hypertension.
He has received the Doctor Honoris Causa Award from the Charles University in Prague (2012), the International Distinguished Medal from the National Kidney Foundation (2007), the Reviewer Award from the Annals of Internal Medicine (2007) and the Josef Schneider Award from the Theresia Foundation (2006). He serves on the advisory board and is a consultant for Boehringer Ingelheim, Reata Pharmaceuticals, AMAG Pharmaceuticals and Baxter. He serves on the speakers’ bureau for Abbott, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Merck and Shire Pharmaceuticals. He has received the 2016 ERO-EDTA Award for Outstanding Clinical Contributions to Nephrology.
Professor Wanner’s research interests focus on the role of lipids in the progression of renal disease, glomerulosclerosis, atherosclerosis in kidney failure patients, elucidation of the inflammatory response syndrome in diabetic nephropathy, chronic kidney disease and kidney failure, diabetes and diabetic nephropathy, and identification of risk factors responsible for progressive kidney and cardiovascular disease in large cohorts of patients with chronic kidney disease.